secwatch / observer
8-K filed April 24, 2023, 7:59 PM ET ticker ESLA CIK 0001844417
other material confidence high sentiment neutral materiality 0.60

TradeUP Acquisition Corp. enters $50M common stock purchase agreement with White Lion Capital

Estrella Immunopharma, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Estrella Immunopharma, Inc. entered into Registration Rights Agreement with White Lion Capital, LLC (effective 2023-04-20).

Action
entry
Agreement
equity purchase
Counterparty
White Lion Capital, LLC
Effective
2023-04-20
Exact text from the filing
Concurrently with the execution of the Common Stock Purchase Agreement, the Company entered into the RRA with the White Lion in which the Company has agreed to register with the SEC the shares of Common Stock purchased by White Lion under the Common Stock Purchase Agreement and the shares of Common Stock to be issued upon the conversion of Estrella Series A Preferred Stock for resale within 30 days of the consummation of the Business Combination.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Estrella Immunopharma, Inc. entered into Common Stock Purchase Agreement with White Lion Capital, LLC valued at up to $50,000,000 (effective 2023-04-20).

Action
entry
Agreement
equity purchase
Counterparty
White Lion Capital, LLC
Value
up to $50,000,000
Effective
2023-04-20
Exact text from the filing
On April 20, 2023, TradeUP Acquisition Corp. (the “Company”) entered into a common stock purchase agreement (the “Common Stock Purchase Agreement”) and a related registration rights agreement (the “RRA”) with White Lion Capital, LLC, a Nevada limited liability company (“White Lion”).
View on SEC.gov

Browse all material agreements →

Estrella Immunopharma, Inc. filing history →

Source: SEC EDGAR
accession 0001575872-23-000606
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.